Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...

A pharmaceutical company based in New Jersey that’s known for its FDA-approved treatment for ALS is set to be acquired for $2.5 billion. Tanabe Pharma America, which operates a U.S. headquarters in ...

Bill and Renee Stegemerten had a favorite bike route near their home on the outskirts of Stuttgart where they enjoyed the trails on weekend outings. Then 53-year-old Renee, always steady on the bike, ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline of neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...